Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

[18F]choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy: influence of antiandrogen therapy - a preliminary study.

Henninger B, Vesco P, Putzer D, Kendler D, Loizides A, Bale RJ, Virgolini IJ.

Nucl Med Commun. 2012 Aug;33(8):889-94. doi: 10.1097/MNM.0b013e328355990f.

PMID:
22692582
2.

Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.

Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S.

J Nucl Med. 2009 Sep;50(9):1394-400. doi: 10.2967/jnumed.108.061507. Epub 2009 Aug 18. Erratum in: J Nucl Med. 2009 Oct;50(10):1578.

3.

[PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].

García JR, Soler M, Blanch MA, Ramírez I, Riera E, Lozano P, Pérez X, Delgado E, Carrio I, Lomeña F.

Rev Esp Med Nucl. 2009 May-Jun;28(3):95-100. Spanish.

4.

18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.

Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, Soloviev D, Hany TF, Miralbell R.

BJU Int. 2007 Jun;99(6):1415-20. Epub 2007 Apr 8.

5.

Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer.

Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, Mancini M.

Radiol Med. 2008 Sep;113(6):895-904. doi: 10.1007/s11547-008-0263-8. Epub 2008 Apr 14. English, Italian.

PMID:
18414809
6.

Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

Heinisch M, Dirisamer A, Loidl W, Stoiber F, Gruy B, Haim S, Langsteger W.

Mol Imaging Biol. 2006 Jan-Feb;8(1):43-8.

PMID:
16315004
7.

Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.

Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R, Gschwend JE.

BJU Int. 2007 Oct;100(4):786-93.

8.

Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography.

Breeuwsma AJ, Pruim J, van den Bergh AC, Leliveld AM, Nijman RJ, Dierckx RA, de Jong IJ.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):160-4. doi: 10.1016/j.ijrobp.2009.04.090. Epub 2009 Sep 23.

PMID:
19783375
9.

[11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen.

Giovacchini G, Picchio M, Garcia-Parra R, Mapelli P, Briganti A, Montorsi F, Gianolli L, Messa C.

J Urol. 2013 Jan;189(1):105-10. doi: 10.1016/j.juro.2012.09.001. Epub 2012 Nov 16.

PMID:
23164385
10.

[(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy.

Rinnab L, Simon J, Hautmann RE, Cronauer MV, Hohl K, Buck AK, Reske SN, Mottaghy FM.

World J Urol. 2009 Oct;27(5):619-25. doi: 10.1007/s00345-009-0371-7. Epub 2009 Feb 21.

PMID:
19234708
11.

Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer.

Souvatzoglou M, Krause BJ, Pürschel A, Thamm R, Schuster T, Buck AK, Zimmermann F, Molls M, Schwaiger M, Geinitz H.

Radiother Oncol. 2011 May;99(2):193-200. doi: 10.1016/j.radonc.2011.05.005. Epub 2011 May 26.

PMID:
21620494
12.

11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer.

de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ.

Eur Urol. 2003 Jul;44(1):32-8; discussion 38-9.

PMID:
12814672
13.

2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.

Schöder H, Herrmann K, Gönen M, Hricak H, Eberhard S, Scardino P, Scher HI, Larson SM.

Clin Cancer Res. 2005 Jul 1;11(13):4761-9.

14.

¹⁸F-choline positron emission tomography/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: feasibility study in 60 patients.

D'Angelillo RM, Sciuto R, Ramella S, Papalia R, Jereczek-Fossa BA, Trodella LE, Fiore M, Gallucci M, Maini CL, Trodella L.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):296-302. doi: 10.1016/j.ijrobp.2014.05.050. Epub 2014 Jul 29.

PMID:
25084612
15.

[Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma].

Moussaid Y, Bonardel G, Jacob J, Métivier D, Gontier E, Bauduceau O, Durand X, Fayolle M, Houlgatte A, Foehrenbach H, Védrine L, Chargari C.

Cancer Radiother. 2013 Jul-Aug;17(4):259-64. doi: 10.1016/j.canrad.2013.01.019. Epub 2013 May 20. French.

PMID:
23702489
16.

Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.

Schilling D, Schlemmer HP, Wagner PH, Böttcher P, Merseburger AS, Aschoff P, Bares R, Pfannenberg C, Ganswindt U, Corvin S, Stenzl A.

BJU Int. 2008 Aug;102(4):446-51. doi: 10.1111/j.1464-410X.2008.07592.x. Epub 2008 Apr 11.

17.

Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.

Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, Cozzarini C, Di Muzio N, Rigatti P, Fazio F, Messa C.

Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):301-9. doi: 10.1007/s00259-009-1253-3. Epub 2009 Sep 15.

PMID:
19756592
18.

Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).

Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, Gentile V, Laghi A, Passariello R.

Eur J Radiol. 2012 Apr;81(4):700-8. doi: 10.1016/j.ejrad.2011.01.095. Epub 2011 Feb 17.

PMID:
21330082
19.

Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.

Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.

BJU Int. 2015 Jun;115(6):874-83. doi: 10.1111/bju.12953. Epub 2015 Jan 21.

PMID:
25307619
20.

(11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.

Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C, Ambrosini V, Boschi S, Martorana G, Fanti S.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):149-55. doi: 10.1007/s00259-012-2272-z. Epub 2012 Nov 14.

PMID:
23151910
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk